Induction Systemic Chemotherapy for Breast Cancer

2011 ◽  
pp. 127-137 ◽  
Author(s):  
Maria Angeles Gil-Delgado ◽  
François-Michel Delgado ◽  
David Khayat
Breast Care ◽  
2006 ◽  
Vol 1 (6) ◽  
pp. 358-361
Author(s):  
Wolfgang Eiermann ◽  
Beyhan Ataseven

2018 ◽  
Vol 150 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Alessandra Landmann ◽  
Daniel J Farrugia ◽  
Li Zhu ◽  
Emilia J Diego ◽  
Ronald R Johnson ◽  
...  

Author(s):  
Yoriko Murata ◽  
Yasuhiro Ogawa ◽  
Isamu Yokoe ◽  
Shinji Kariya ◽  
Kazuo Morio ◽  
...  

2019 ◽  
Vol 13 (2) ◽  
pp. 121-123
Author(s):  
Martina Finocchi ◽  
Ombretta Para ◽  
Giacomo Zaccagnini ◽  
Lorenzo Corbo ◽  
Lucia Maddaluni ◽  
...  

It is known that a wild spectrum of hepatic manifestations can be common presentations of metastatic breast cancer. Pseudocirrhosis pattern has been often described as almost always secondary to systemic chemotherapy and it is defined by morphological liver changes that mimic cirrhosis including capsular retraction, nodularity, parenchyma atrophy and caudate lobe, radiologically identifiable. Acute liver injury is an occasional complication in oncologic patients, and it outlines an organ failure when there is evidence of encephalopathy and coagulopathy (international normalized ratio >1.5) in the absence of pre-existing liver disease, with an illness of <26 weeks duration. The two most common etiologies are leukemia/lymphoma followed by breast cancer but also in this case, liver is involved almost always after chemotherapy, hormonotherapy or radiotherapy. Here we present a case of rapid evolving acute liver failure presented as cryptogenic pseudocirrhosis without any evidence of primitive breast cancer but an incidental demonstration.


2019 ◽  
Vol 17 (2) ◽  
pp. 118-126 ◽  
Author(s):  
Matthew P. Goetz ◽  
William J. Gradishar ◽  
Benjamin O. Anderson ◽  
Jame Abraham ◽  
Rebecca Aft ◽  
...  

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.


2006 ◽  
Vol 182 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Sandra J. Roddiger ◽  
Christos Kolotas ◽  
Ineza Filipowicz ◽  
Ralf Kurek ◽  
Ralph Paul Kuner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document